Endomag is now part of Hologic
Hologic, Inc., a global leader in women’s health, has completed its previously announced acquisition of Endomagnetics Ltd (Endomag), for approximately $310 million.
Endomag wins King’s Award For Enterprise In International Trade Category
Cambridge, UK - Endomag, one of the UK's fastest-growing MedTech companies, specialising in devices used for the treatment of breast cancer, has been recognised for its impressive growth in the UK and overseas with a 2024 King's Award for Enterprise.
Endomag being sold to US firm for $310m
Cambridge breast cancer pioneer Endomag is set to become the latest UK bio business snapped up by America. The privately owned company is to be acquired by Hologic Inc – a NASDAQ-quoted firm based in Marlborough, Massachusetts – for $310 million.
Endomag: New procedure spares women with breast cancer from unnecessary surgical complication
Targeted Axillary Dissection (TAD) is a new surgical technique that allows surgeons to assess cancer in specific lymph nodes while minimising the patient’s risk of developing lymphedema linked to their treatment.
![330 Cambridge Science Park [copyright – Bidwells]](/sites/default/files/styles/article_card/public/330%20Cambridge%20Science%20Park.jpg?itok=cuWs6Gno)
Endomag secures Cambridge Science Park space for new UK headquarters
Endomag, a breast cancer surgical guidance company and one of the UK’s fastest-growing private technology businesses, has secured 20,386 sq ft of space at 330 Cambridge Science Park. Advised by Carter Jonas, Endomag has agreed a ten-year lease at the world-renowned Science Park location.
NICE issues a positive medtech innovation briefing for Endomag’s Magtrace® breast cancer lymphatic tracer
Endomag’s lymphatic tracer, Magtrace®, has received a positive Medtech Innovation Briefing (MIB) from the National Institute for Health and Care Excellence (NICE) for locating sentinel lymph nodes.
Endomag wins second Queen’s Award for Enterprise
Endomag has been officially honoured with a 2021 Queen’s Award for Enterprise in International Trade.
Endomag named one of Europe’s fastest growing companies by the Financial Times
Endomag has been officially named as one of the ‘FT 1000: Europe’s Fastest Growing Companies of 2021’, as published in a recent edition of the Financial Times newspaper. Three other Cambridge Network member companies also feature in the list.
Endomag secures £15 million ($20 million) in Series D funding
Endomag, a breast cancer market leader and one of the UK’s fastest growing private technology businesses1, has secured £15m (~$20m) in Series D funding. These funds are earmarked for expanding access to new advanced techniques enabled by its products, such as targeted axillary dissection (TAD) and delayed sentinel lymph node biopsy (dSLNB). The funds will also be used to scale its product…
Endomag CEO features in Telegraph article about Brexit transition
Eric Mayes, CEO of Cambridge-based Endomag, tells The Telegraph that thorough preparation has made his firm future-proof, as businesses across the UK prepare for the end of the Brexit transition period on 31 December.